Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI ACWI ETF (ACWI) vs Quest Diagnostics Inc (DGX) Price & Performance

iShares MSCI ACWI ETF
Quest Diagnostics Inc

Price performance

Price movement over the last 24 hours

Key statistics

iShares MSCI ACWI ETF vs Quest Diagnostics Inc — how do they compare? iShares MSCI ACWI ETF trades at $155.55, while Quest Diagnostics Inc trades at $207.95 (market cap $23.51B). The key difference: Quest Diagnostics Inc pays a 1.62% dividend while iShares MSCI ACWI ETF pays none. Which is the better fit depends on your goals.

ACWIDGX
52-Week High
$159.97$216.02
52-Week Low
$128.32$166.42
Market Cap
$23.51B
Sector
Health
Enterprise Value
$29.52B
Dividend Yield
1.62%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI ACWI ETF

ACWI trades at $157.97, up 1.17% with a bullish technical signal from moving averages. The ETF shows strong institutional interest and positive news flow, with a dividend scheduled for June 2026. Key support lies at $156, while resistance is at $159.

Outlook remains positive due to robust EPS growth and investor inflows into global equity ETFs. Risks include overbought technical conditions and market volatility. The stock's valuation and momentum support a constructive view for long-term investors.

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $212.38, down 1.55% today but remains near its 52-week high. The stock shows strong fundamental performance with three consecutive quarterly earnings beats and revenue growth to $11.04 billion in 2025. Technical indicators suggest a bullish trend with support at $212 and resistance at $216. Recent positive developments include New York State approval for the Haystack MRD cancer test, expanding market reach.

DGX presents a balanced investment case with solid fundamentals and analyst support, though valuation appears full. The consensus price target of $222.80 offers modest upside. Key risks include healthcare reimbursement pressures and elevated debt levels. Earnings growth and diagnostic service expansion remain primary catalysts for continued performance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI ACWI ETF

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.

Read more on ACWI

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX